Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Emerald Health Launches Sublingual Tablets

Stockhouse Editorial
3 Comments| April 13, 2021

{{labelSign}}  Favorites
{{errorMessage}}


(Image via Emerald Health Therapeutics.)

Emerald Health Therapeutics Inc. (TSX-V: EMH, OTCQX: EMHTF, Forum) launched its new product line, SYNC Tabs onClick to enlarge Tuesday, an innovative, naturally-flavoured ingestible offering consumers a controlled 10 mg THC dose.

EMH President and Chief Executive Officer Riaz Bandali said that this product development efforts are centered on providing consumers with distinctive cannabis products offering controlled, predictable actions – with greater precision of dosing and the onset and offset of effects.

“We have a talented product development team that is passionate about science and innovation. They are moving additional new product lines toward launches planned for the next few months and quarters, which we expect to start positively impacting our growth.”

The tablets are available to consumers at licensed cannabis retailers and online in BC, Manitoba, and Newfoundland, with Alberta to follow.

For more on SYNC Tabs, click here.

As it creates new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products Emerald Health recently began a partnership with Medical Plants SLU, a wholly-owned subsidiary of a high-tech tomato producer with more than 25 years of growing experience, based in Spain.

This partnership will help Medical Plants produce medical cannabis dried flower to serve emerging legal medical cannabis markets in the EU and other countries.

Medical Plants will also produce 2.0 cannabis products and derivatives in addition to high-grade GMP-certified flower. It grows its tomatoes in 40 hectares of state-of-the-art greenhouses with over 500 employees and sells its produce in 17 European countries. Medical Plants is also just only one of five authorized medical cannabis producers in Spain.

CEO Bandali explained that as countries in Europe and elsewhere legalize cannabis use, GMP certification is often a requirement.

“We are pleased to establish this partnership with the successful Cualin team and its new Medical Plants venture, which will give us access to GMP-certified medical cannabis at preferential pricing but without purchase obligations or any capital investment. Medical Plants comes from an excellent pedigree of sophisticated plant-growing history, which along with its ideal location for cost-efficient growing, position it well to become a trusted premiere producer of medical cannabis dried flower.”


FULL DISCLOSURE: Emerald Health Therapeutics Inc. is a client of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company